Fresenius Medical Care AG
XMUN:FME
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.04
42.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FME stock under the Base Case scenario is 49.35 EUR. Compared to the current market price of 42.4 EUR, Fresenius Medical Care AG is Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Fresenius Medical Care AG
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FME cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Fresenius Medical Care AG
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Fresenius Medical Care AG is a global leader in providing products and services for individuals undergoing dialysis as a result of chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company specializes in the development and manufacture of high-quality dialysis equipment and supplies, including dialysis machines and filters. With a network that spans over 150 countries, Fresenius operates numerous dialysis clinics, delivering essential care to a large and growing patient population. Its commitment to innovation and quality care positions it well within the healthcare sector, making it a compelling option for investors seeking exposure in the medical techno...
Fresenius Medical Care AG is a global leader in providing products and services for individuals undergoing dialysis as a result of chronic kidney failure. Founded in 1996 and headquartered in Bad Homburg, Germany, the company specializes in the development and manufacture of high-quality dialysis equipment and supplies, including dialysis machines and filters. With a network that spans over 150 countries, Fresenius operates numerous dialysis clinics, delivering essential care to a large and growing patient population. Its commitment to innovation and quality care positions it well within the healthcare sector, making it a compelling option for investors seeking exposure in the medical technology domain.
As the prevalence of kidney disease rises, driven by factors such as aging populations and increasing diabetes cases, Fresenius Medical Care is poised to capitalize on this expanding marketplace. The company's robust pipeline of therapeutic solutions and its focus on integrating healthcare technologies demonstrate a proactive approach to enhancing patient outcomes. Additionally, Fresenius benefits from a diversified business model that includes both product manufacturing and direct patient care services, which provides resilience against market fluctuations. Investors looking for a company with a strong balance sheet, consistent revenue growth, and a mission-driven approach to healthcare will find Fresenius Medical Care AG to be an attractive choice in their portfolio.
Fresenius Medical Care AG is a global leader in the provision of products and services for individuals undergoing dialysis due to chronic kidney failure. The company's operations can be categorized into several core business segments:
-
Dialysis Services: This segment focuses on providing comprehensive dialysis treatment for patients with end-stage renal disease (ESRD). Fresenius operates a network of outpatient dialysis clinics and provides in-home dialysis options. Their services extend to patient management and support, encompassing both hemodialysis and peritoneal dialysis options.
-
Dialysis Products: This segment involves the manufacturing and supply of medical devices and products used in dialysis treatments. Key products include dialysis machines, dialyzers (artificial kidneys), bloodlines, and other related consumables. These products are essential for the efficient operation of dialysis treatments in clinics and for home dialysis therapies.
-
Care Coordination: Fresenius Medical Care also emphasizes care coordination and integrated care models. This segment involves working closely with healthcare providers to improve outcomes for patients through systematic management of their care, optimizing treatment plans, and providing support services to enhance the overall patient experience.
-
Renal Pharmaceuticals: In addition to its dialysis services and products, Fresenius is involved in the development and distribution of pharmaceuticals specifically tailored for treating renal conditions. This may include medications for managing anemia and mineral and bone disorders common in kidney disease patients.
These core segments collectively allow Fresenius Medical Care to deliver a comprehensive approach to managing kidney disease, focusing on improving patient outcomes while maintaining operational excellence and innovation in a highly competitive healthcare environment.
Fresenius Medical Care AG, a leading provider of products and services for individuals with renal diseases, possesses several unique competitive advantages that distinguish it from its rivals:
-
Vertical Integration: Fresenius Medical Care operates across the entire kidney care value chain, including the production of dialysis products and the provision of dialysis services. This integration allows for greater control over quality, costs, and supply chain efficiencies.
-
Global Presence: With operations in more than 120 countries, Fresenius benefits from economies of scale and can leverage its global reach to optimize resources, share best practices, and enhance its brand recognition.
-
Strong R&D Capabilities: The company invests significantly in research and development, leading to innovative products and therapies in renal care. This emphasis on innovation can result in improved treatment outcomes and a stronger competitive position.
-
Reputation and Trust: As an established leader in the dialysis market, Fresenius has built a strong reputation based on quality and reliability. This brand trust helps in acquiring and retaining both patients and healthcare providers.
-
Comprehensive Patient Care Solutions: Fresenius provides integrated care solutions that extend beyond dialysis machines, including patient education, care coordination, and nutritional advice. This holistic approach can improve patient outcomes and drive loyalty.
-
Specialized Workforce: The company has a highly trained workforce with specialized skills in nephrology, fostering a culture focused on patient care and support. This expertise can lead to superior service delivery.
-
Regulatory Expertise: Operating in a heavily regulated industry, Fresenius has developed substantial experience and knowledge in navigating regulatory challenges, which can serve as a barrier for newer entrants into the market.
-
Partnerships and Collaborations: Fresenius maintains strong relationships with healthcare providers, hospitals, and government institutions, allowing it to secure favorable contracts and improve patient access to care.
-
Diversified Revenue Streams: In addition to dialysis services, Fresenius engages in the manufacture and sales of dialysis equipment, pharmaceuticals, and other related products. This diversification helps mitigate risks associated with reliance on a single revenue source.
-
Focus on Quality Improvement and Cost Efficiency: The company employs continuous improvement processes and data analytics to enhance service delivery and streamline operations, which can translate into cost savings and improved patient satisfaction.
These competitive advantages enable Fresenius Medical Care to maintain a strong position in the renal care market, ensuring its resilience against competitive pressures.
Fresenius Medical Care AG, a leading provider of products and services for individuals with chronic kidney failure, faces several risks and challenges in the near future:
-
Regulatory and Compliance Risks: The healthcare sector is subject to extensive regulations. Changes in laws or regulations, such as those related to reimbursement rates or patient safety standards, can significantly impact Fresenius Medical Care's operations and profitability.
-
Market Competition: The dialysis market is becoming increasingly competitive, with new entrants and advancements in technology. Competing firms may offer innovative solutions or better pricing, which could threaten Fresenius's market share.
-
Economic Conditions: Economic downturns can affect healthcare spending. As a provider dependent on reimbursement models primarily from government programs and private insurers, changes in the economic climate could impact revenues.
-
Technological Advancements: Rapid changes in medical technology require continual investment in research and development. Failure to keep up with technological advancements or to innovate could hinder Fresenius's competitive position.
-
Global Supply Chain Disruptions: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. Continued disruptions could impact the supply of medical devices and consumables necessary for dialysis treatments.
-
Distribution and Access: Challenges related to expanding access to care in various regions, particularly in emerging markets, could limit growth opportunities in new geographical areas.
-
Costs and Profit Margins: Pressure on healthcare costs, especially in developed markets, can squeeze profit margins. This includes accounting for increasing costs associated with raw materials, labor, and compliance.
-
Demographic Changes: The rise in aging populations leads to increased demand for dialysis services; however, it also means that more patients may have multiple comorbidities, complicating treatment and potentially increasing costs.
-
Reimbursement Pressure: Changes in reimbursement policies (including value-based care initiatives) might pressure traditional revenue models, impacting profitability.
-
Mergers and Acquisitions: As consolidation continues in the healthcare sector, Fresenius may face competitive pressures from newly formed entities that can leverage synergies and scale to offer more comprehensive services at lower costs.
Understanding these risks and addressing them proactively will be essential for Fresenius Medical Care AG to maintain its leadership position and drive sustainable growth.
Revenue & Expenses Breakdown
Fresenius Medical Care AG
Balance Sheet Decomposition
Fresenius Medical Care AG
Current Assets | 8.7B |
Cash & Short-Term Investments | 1.4B |
Receivables | 4.1B |
Other Current Assets | 3.2B |
Non-Current Assets | 25.2B |
Long-Term Investments | 1.4B |
PP&E | 7.3B |
Intangibles | 16.2B |
Other Non-Current Assets | 409.6m |
Current Liabilities | 5.9B |
Accounts Payable | 783.7m |
Short-Term Debt | 322m |
Other Current Liabilities | 4.8B |
Non-Current Liabilities | 14B |
Long-Term Debt | 10.3B |
Other Non-Current Liabilities | 3.7B |
Earnings Waterfall
Fresenius Medical Care AG
Revenue
|
19.4B
EUR
|
Cost of Revenue
|
-14.5B
EUR
|
Gross Profit
|
4.9B
EUR
|
Operating Expenses
|
-3.6B
EUR
|
Operating Income
|
1.4B
EUR
|
Other Expenses
|
-828.5m
EUR
|
Net Income
|
530.3m
EUR
|
Free Cash Flow Analysis
Fresenius Medical Care AG
EUR | |
Free Cash Flow | EUR |
In the third quarter of 2024, Fresenius Medical Care achieved a 2% organic revenue growth despite a 0.7% decline on a revenue outlook basis, attributed mainly to divestitures that impacted growth by 2.3%. Operating income rose by 10%, lifting the margin to 9.8%. With successful execution of the FME25 program, expected savings increased to €200 million for 2024, ahead of the €100 million to €150 million guidance. For 2024, the company confirms revenue growth expectations and now anticipates operating income growth of 16% to 18%. Looking ahead, the 2025 margin target remains at 10% to 14%.
What is Earnings Call?
FME Profitability Score
Profitability Due Diligence
Fresenius Medical Care AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Fresenius Medical Care AG's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
FME Solvency Score
Solvency Due Diligence
Fresenius Medical Care AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Fresenius Medical Care AG's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FME Price Targets Summary
Fresenius Medical Care AG
Dividends
Current shareholder yield for FME is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fresenius Medical Care AG & Co. KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 123,106 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The firm also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The firm supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Contact
IPO
Employees
Officers
The intrinsic value of one FME stock under the Base Case scenario is 49.35 EUR.
Compared to the current market price of 42.4 EUR, Fresenius Medical Care AG is Undervalued by 14%.